DNAnexus expands with Microsoft Azure Cloud Platform

At DNAnexus we focus on enabling scientific research and discovery by removing barriers such as data compliance and security concerns, allowing our global community of customers to focus on innovation, not logistics. DNAnexus is the only cloud-based translational informatics platform that offers regional services in China, North America, Europe, and Asia Pacific, and now, we are pleased to offer our customers a second region in Europe, Microsoft Azure’s West Europe.

Data generated in the EU is subject to strict European privacy regulations. DNAnexus has adopted policies and implemented new procedures that comply with European regulations. Consequently, DNAnexus users based in the European countries can upload genomic data from individuals in those countries to DNAnexus in compliance with European data privacy laws and regulations (e.g. GDPR) and stay in compliance with regulations regarding data localization.

The additional region in Europe will address the needs of the growing European BioPharma and Precision Medicine customers, allowing them to seamlessly access the Azure cloud platform via DNAnexus while complying with European regulations, including the GDPR and other data privacy regulations. Organizations will be able to collaborate with research centers in the EU and across the globe to analyze biomedical data on one common platform, while still maintaining compliance with European regulations.  The DNAnexus Platform allows data owners the ability to set up compliance policies and enforce local/regional restrictions around their data, eliminating the confusion and potential risks of collaborating globally.

Other security features enable researchers to log, monitor, and block any unauthorized data access and prevent users from downloading or copying data outside of their regional boundaries. These features, in addition to industry-leading data management, workflow and data provenance tracking features of the DNAnexus Platform, provide an environment to work with large-scale biomedical and genomics data that complies with EU GDPR and other data privacy regulations, enabling customers to focus on scientific discovery – not compliance.

You can find out more about DNAnexus expansion and offerings at Bio-IT World. Visit DNAnexus in booth #310 and learn more about our conference activities on our blog. You can also stop by our demo session at Microsoft booth #446 on Wednesday, May 16th at 3:30pm.

Bio-IT World 2018: Transforming Biological Insights to Accelerate Translational Research

Bio-IT World 2018 Logo

Bio-IT World is right around the corner! We are excited to once again join over 3,400 researchers, clinicians, pharmaceutical and IT professionals attending the conference in Boston next week. The DNAnexus team will be stationed in booth #310, so stop by to learn how DNAnexus streamlines the use of next-generation sequencing (NGS) data to accelerate translational research.

Best Practices FinalistCongratulations to the Human Genome Sequencing Center (HGSC) at Baylor College of Medicine for being one of this year’s Best Practices Award Finalist in the IT infrastructure/HPC category. Their work developing novel at-scale methods for human genome sequencing resulted in the world’s largest known full-spectrum variant genotype analyses of more than 22,000 human whole genomes. As a valued industry partner, we are extremely excited for HGSC to be distinguished by this honor.

We are especially excited to announce the DNAnexus Translational Informatics Suite (TIS). This specialized suite of tools transforms biological insights and research data by exploring new approaches to integration, visualization, analysis, and application of biological and clinical trial data, including big data analytics and deep learning/AI.

Best of Show FinalistWe will also be showcasing our Clinical Trials Solution, a 2018 Best of Show Award Finalist in the Genomic Data Services Category. This award identifies exceptional innovation in technologies used by life science professionals today and we are honored to be considered.

See our full list of in-booth demos and activities at Bio-IT World below. Can’t make it to one of our events? Our booth (#310) will serve as homebase to showcase our recent projects and collaborations. Stop by anytime during the conference, or email us to schedule a meeting with a member of our team.

Poster

VGP LogoBuilding Reference Quality Genome Assemblies Using DNAnexus
Presenter: Maria Simbirsky, PhD, Bioinformatics Scientist

DNAnexus is the supporting platform for the Genome 10K’s Vertebrate Genome Project (VGP), which assembles and analyzes genomes of all vertebrate species to create a digital Genome Ark library and help document species that are on the brink of extinction. Maria will be by her poster to answer questions during refreshment breaks, or can discuss the project in DNAnexus booth #310.

Presentations Featuring DNAnexus

Regeneron Genetics CenterIt’s Raining Exomes: Cloud-Enabled Genomics – Handling >250 Samples
Wed, May 16 – 2:25pm
Cloud Computing Track
Speaker: John Penn, PhD, Regeneron Genetics Center

Building a GxP Validated Platform for NGS Analysis Pipelines
Wed, May 16 – 4:30pm
Next-Gen Sequencing Informatics Track
Speaker: Anthony Rowe, PhD

St Jude Children's Research HospitalAdvancing Clinical NGS Test Development Using Thousands of Pediatric Cancer Samples on St. Jude Cloud
Thurs, May 17 – 11:30am
Cancer Informatics and NGS Informatics tracks
Speaker: Michael Rusch, St Jude Children’s Research Hospital

DNAnexus Booth Activities

Clinical Trial Hour

Demo: Incorporating Genomics in Clinical Trials with the DNAnexus CTS
Wednesday May 16, 10:00-11:00am
DNAnexus Booth #310

Promoting a drug from the laboratory and preclinical testing arena into first-in-human studies and later phase clinical trials represents the largest, most costly gamble in the drug discovery pipeline. DNAnexus de-risks this process by enabling companies to transition validated NGS pipelines from translational research into clinical development and, for approved drugs and devices, into clinical and companion diagnostics, all in compliance with HIPAA, CAP/CLIA, and GxP regulations.Best of Show Finalist

Join us for a demo to see how the Best-of-Show-Finalist DNAnexus Clinical Trials Solution (CTS) enables movement of data and pipelines from research into regulated environments.

Translational Informatics Hour

Sneak Peek: Unlocking Insights from Multi-Omics Data with the DNAnexus Translational Informatics Solution
Thursday May 17, 10:00-11:00am
DNAnexus Booth #310

Underlying the explosive growth of multi-omics data is the promise of improved understanding of human biology and disease. However, without the proper tools, scientists are faced with the challenge of analyzing the massive amounts of data to extract insights which can lead to effective therapies. DNAnexus Translational Informatics Suite (TIS) empowers researchers along each step of the discovery process with features such as interactive data exploration, synthetic cohort creation, and scalable analytics, all powered and secured by the DNAnexus cloud.

Stop by our booth on Thursday morning and learn about our translational informatics early access program..

Microsoft Partner Spotlight
Wednesday May 16, 3:30-4:00pm
Microsoft Booth #446

Learn how DNAnexus and Microsoft are leading the charge in accelerating insights, enabling more precise treatments, and furthering patient health. As partners, we are developing solutions in a seamless and scalable manner while adhering to a level of security and compliance required to work with healthcare data. Join us in Microsoft booth #446 for an overview on how our combined industry knowledge and expanded reach enables global collaboration and is solving the most challenging diseases in the market today.

 

 

Shaping the Future of Precision Medicine for Newborns

A Recap of Frontiers in Pediatric Genomic Medicine Conference

Rady Children’s Institute for Genomic Medicine’s (RCIGM) Frontiers in Pediatric Genomic Medicine Conference took place last week on the scenic shores of La Jolla, California. The third annual conference brought together innovators from children’s hospitals and genetics labs around the world who are making big strides in the field of pediatric genomics.  

The meeting began each day with a poignant patient story. Parents held their infant on stage while sharing the story of the very emotionally-trying start to their baby’s life. In all cases these babies were admitted to Rady’s NICU at less than one week old with unexplainable medical conditions linked to the nervous system. With no immediate diagnosis, the newborns’ bodies rapidly were shutting down, and in each case, the parents were told they would likely lose their baby.

With the parents consent, the newborns underwent rapid whole-genome sequencing (rWGS) to try and determine the cause of their symptoms. Leveraging Rady’s rWGS pipeline results were turned around in about a day. In each case, rWGS enabled the team at Rady’s to successfully identify a rare but treatable genetic disorder so the newborn could undergo targeted therapy to dramatically alter the course of the disease. The babies were able to be taken home from the NICU shortly after diagnosis, and are healthy and happy today.

Multiple technology partners power RCIGM’s workflow to deliver this rapid and life-changing diagnosis. The institute uses Illumina NovaSeq for 40x sequencing, followed by rapid alignment and variant calling with Edico Genome’s DRAGEN pipeline. Copy number variation (CNV) analysis is performed on DNAnexus and combined with the file from DRAGEN. The combined VCF is then uploaded to Fabric Genomics for interpretation and reporting. Together with their partners, RCIGM has reduced the WGS turnaround time from a few weeks to under 36 hours.

Throughout the conference, other organizations shared their success stories of whole genome or exome sequencing for rapid diagnosis in newborns. Speakers also made a financial case for performing genomic sequencing on newborns, demonstrating that healthcare costs saved by a reduced length of hospitalization and ongoing care add up to more than the investment for sequencing. It is possible to save lives without increasing costs, a win-win for everyone.   

Hearing case study after case study of successful and rapid diagnosis with genomic sequencing in newborns drove home the message that the medical community is seeing concrete value in investing in rWGS. Further, as sequencing and bioinformatics technology continues to improve, physicians will have earlier access to genomic information to inform treatment decisions. As rWGS continues to gain momentum, genomic testing can become more universally available so newborns and their families can get the right diagnosis and the right treatment in time.